<DOC>
	<DOCNO>NCT02041338</DOCNO>
	<brief_summary>There standard neodjuvant regimen adapt accord different subtypes breast cancer . This phase 2 , randomize study evaluate several regimen different subtypes breast cancer .</brief_summary>
	<brief_title>Study Optimizing Neoadjuvant Regimens Subtypes Breast Cancer</brief_title>
	<detailed_description>Breast cancer heterogenous disease least 4 intrinsic subtypes include Luminal A , Luminal B , HER2 enrich , Basal-like normal breast like . Different subtypes different prognosis treatment sensitivity . Thus , would suitable administer different chemo-regimen different subtypes . This especially true neoadjuvant chemotherapy set standard regimen ever establish . Therefore , design phase 2 randomized clinical trial explore potential effective regimen variable subtypes breast cancer neoadjuvant treatment . Patients first classify Luminal type , Her2 positive type triple-negative type immunohistochemistry exam ER/PR/HER2 core needle biopsy randomize receive either dose dense paclitaxel Luminal type dose dense paclitaxel plus carboplatin without trastuzumab HER2 positive type dose dense paclitaxel plus carboplatin triple-negative type.The control group subtype receive paclitaxel plus epirubicin every 3 week . The duration treatment 4-6 cycle . Primary endpoint pathological CR rate subtypes . Secondary endpoint include disease free survival , objective response rate , safety . Tissue sample blood sample collect baseline treatment . There exploratory biomarkers analyse identify predictive marker efficacy every subtypes .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Stage IIaIIIc breast cancer patient plan receive neoadjuvant chemotherapy Patients enough tissue sample IHC test subtype classification Patients least one measurable lesion accord RECIST1.1 KPS≥80 No prior treatment breast cancer Adequate bone marrow ( neutrophil count ≥1500 ml platelet count ≥100,000 ml ) , renal ( serum creatinine &lt; 1.5 time upper limit normal [ ULN ] creatinine clearance ≥60 ml/minute ) , hepatic ( total bilirubin ≤1.5 ULN ; alanine aminotransferase , aspartate aminotransferase , alkaline phosphatase ≤2.5 ULN ) , cardiac function ( assessed electrocardiogram thoracic radiography ) require . Fertile woman exclude pregnant lactate use adequate contraception . Previous chemotherapy breast cancer . history serious illness ( e.g . congestive heart failure , angina pectoris , uncontrolled hypertension arrhythmia , clinically significant neurologic psychiatric disorder , uncontrolled serious infection , AIDS ) , organ allograft , severe gastrointestinal disorder , neoplasia ( except situ cervical cancer , nonmelanoma skin cancer , previous diagnosis cancer evidence disease &gt; 10 year ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>